Onconetix, Inc. (ONCO)
NASDAQ: ONCO · Real-Time Price · USD
1.430
-0.090 (-5.92%)
Dec 26, 2025, 4:00 PM EST - Market closed
Onconetix Employees
Onconetix had 5 employees as of December 31, 2024. The number of employees decreased by 7 or -58.33% compared to the previous year.
Employees
5
Change (1Y)
-7
Growth (1Y)
-58.33%
Revenue / Employee
$244,750
Profits / Employee
-$10,169,074
Market Cap
2.22M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5 | -7 | -58.33% |
| Dec 31, 2023 | 12 | 0 | - |
| Dec 31, 2022 | 12 | 7 | 140.00% |
| Dec 31, 2021 | 5 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ONCO News
- 3 months ago - Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc. - GlobeNewsWire
- 3 months ago - Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement - GlobeNewsWire
- 3 months ago - Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM - GlobeNewsWire
- 5 months ago - Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement - GlobeNewsWire
- 6 months ago - Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel - GlobeNewsWire
- 7 months ago - Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders - GlobeNewsWire
- 7 months ago - Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq - GlobeNewsWire
- 7 months ago - Onco-Innovations Uplists to Cboe Canada - Business Wire